Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.66

(-2.24%)

Gross Profit Summary of Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.'s latest annual gross profit in 2023 was -3.09 Million EUR , down -1896.89% from previous year.
Vivoryon Therapeutics N.V.'s latest quarterly gross profit in 2024 Q2 was -73 Thousand EUR , down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported a annual gross profit of -161 Thousand EUR in annual gross profit 2022, down -101.78% from previous year.
Vivoryon Therapeutics N.V. reported a annual gross profit of 9.03 Million EUR in annual gross profit 2021, up 6284.93% from previous year.
Vivoryon Therapeutics N.V. reported a quarterly gross profit of -79 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported a quarterly gross profit of -3.21 Million EUR for 2023 FY, down -1896.89% from previous quarter.

Annual Gross Profit Chart of Vivoryon Therapeutics N.V. (2023 - 2011)

Historical Annual Gross Profit of Vivoryon Therapeutics N.V. (2023 - 2011)

Year	Gross Profit	Gross Profit Growth
2023	-3.09 Million EUR	-1896.89%
2022	-161 Thousand EUR	-101.78%
2021	9.03 Million EUR	6284.93%
2020	-146 Thousand EUR	-65.91%
2019	-88 Thousand EUR	-282.61%
2018	-23 Thousand EUR	78.3%
2017	-106 Thousand EUR	-9.28%
2016	-97 Thousand EUR	-73.21%
2015	-56 Thousand EUR	0.0%
2014	- EUR	0.0%
2013	- EUR	-100.0%
2012	6000.00 EUR	-71.43%
2011	21 Thousand EUR	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	-73 Thousand EUR	0.0%
2023 Q2	-79 Thousand EUR	0.0%
2023 FY	-3.21 Million EUR	-1896.89%
2023 Q4	-4.14 Million EUR	0.0%
2022 FY	-161 Thousand EUR	-101.78%
2022 Q2	-81 Thousand EUR	0.0%
2022 Q4	-80 Thousand EUR	0.0%
2021 Q4	9.11 Million EUR	0.0%
2021 Q2	-83 Thousand EUR	0.0%
2021 FY	9.03 Million EUR	6284.93%
2020 FY	-146 Thousand EUR	-65.91%
2020 Q4	-82 Thousand EUR	0.0%
2020 Q2	-64 Thousand EUR	0.0%
2019 Q4	-63 Thousand EUR	0.0%
2019 FY	-88 Thousand EUR	-282.61%
2019 Q2	-25 Thousand EUR	0.0%
2018 Q2	- EUR	0.0%
2018 Q4	- EUR	0.0%
2018 FY	-23 Thousand EUR	78.3%
2017 Q2	- EUR	0.0%
2017 FY	-106 Thousand EUR	-9.28%
2017 Q4	- EUR	0.0%
2016 FY	-97 Thousand EUR	-73.21%
2016 Q4	- EUR	0.0%
2016 Q2	- EUR	0.0%
2015 FY	-56 Thousand EUR	0.0%
2015 Q2	- EUR	0.0%
2015 Q4	- EUR	0.0%
2014 Q2	- EUR	0.0%
2014 FY	- EUR	0.0%
2014 Q4	- EUR	0.0%
2013 Q4	- EUR	0.0%
2013 FY	- EUR	-100.0%
2013 Q3	- EUR	0.0%
2013 Q2	- EUR	0.0%
2013 Q1	- EUR	0.0%
2012 Q1	1500.00 EUR	0.0%
2012 Q3	1500.00 EUR	0.0%
2012 Q4	- EUR	-100.0%
2012 FY	6000.00 EUR	-71.43%
2012 Q2	1500.00 EUR	0.0%
2011 Q4	1500.00 EUR	-71.43%
2011 Q1	5250.00 EUR	0.0%
2011 Q3	5250.00 EUR	0.0%
2011 Q2	5250.00 EUR	0.0%
2011 FY	21 Thousand EUR	0.0%
2010 Q4	5250.00 EUR	0.0%

Peer Gross Profit Comparison of Vivoryon Therapeutics N.V.

Name	Gross Profit	Gross Profit Difference
Boiron SA	358.08 Million EUR	100.864%
Laboratorios Farmaceuticos Rovi, S.A.	483.34 Million EUR	100.64%
Vetoquinol SA	291.37 Million EUR	101.062%
Valneva SE	52.83 Million EUR	105.858%
AB Science S.A.	587 Thousand EUR	627.257%
Nanobiotix S.A.	42.35 Million EUR	107.307%
PHAXIAM Therapeutics S.A.	1.32 Million EUR	333.409%
BioSenic S.A.	543 Thousand EUR	669.982%
ABIVAX Société Anonyme	3.91 Million EUR	179.075%
Formycon AG	23.3 Million EUR	113.28%